OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL-Reference-Cited by-同舟云学术

OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL

Published:2019-04-23 Issue:14 Volume:25 Page:4493-4503
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Evans Kathryn,Duan JianXin,Pritchard Tara^ORCID,Jones Connor D.,McDermott Lisa,Gu Zhaohui,Toscan Cara E.^ORCID,El-Zein Narimanne,Mayoh Chelsea^ORCID,Erickson Stephen W.,Guo Yuelong,Meng Fanying,Jung Donald,Rathi Komal S.,Roberts Kathryn G.,Mullighan Charles G.^ORCID,Shia Chi-Sheng,Pearce Tillman,Teicher Beverly A.,Smith Malcolm A.,Lock Richard B.

Funder

NCI

NHMRC

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhanced pharmacological activities of AKR1C3‐activated prodrug AST‐3424 in cancer cells with defective DNA repair;International Journal of Cancer;2024-09-07

2. Creation of signatures and identification of molecular subtypes of glioblastoma based on disulfidptosis-related genes for predicting patient prognosis and immunological activity;Asian Journal of Surgery;2024-08

3. Advances in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia;Blood Reviews;2024-07

4. Prodrugs: A Novel Approach of Drug Delivery;International Journal of Pharmacy and Chemistry;2024-06-29

5. In vivo activity of the second-generation proteasome inhibitor ixazomib against pediatric T-cell acute lymphoblastic leukemia xenografts;Experimental Hematology;2024-04